Prostate Cancer : Episode 4

Video

Episode 4 - Treatment Guidelines and Economic Considerations

During this segment, Raoul S. Concepcion, MD, explains how the rapid development of agents for castration-resistant prostate cancer (CRPC) has led to an expanding number of clinical guidelines, developed by multiple organizations, for clinicians’ use during important treatment-decisions.

However, he explains that the treatment options recommended in these guidelines are expensive, creating a challenge to both clinicians and payers.

To clarify misconceptions about medical policy and coverage for patients with CRPC, Michael Kolodziej, MD, discusses the variables that payers consider when making decisions about coverage for these expensive treatment options.


Related Videos
Dr Emma Achola-Kothani
Nini Wu, MD, Navista
Dr Emma Achola-Kothari
John Barkett, MBA
CK Wang, MD, COTA
John Barkett, MBA
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Eboni Price-Haywood, MD and Toni Flowers, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo